Corvus Pharmaceuticals CRVS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's retained earnings?
- Corvus Pharmaceuticals (CRVS) reported retained earnings of -$425.99M in Q1 2026.
- How has Corvus Pharmaceuticals's retained earnings changed year-over-year?
- Corvus Pharmaceuticals's retained earnings decreased by 11.6% year-over-year, from -$381.82M to -$425.99M.
- What is the long-term trend for Corvus Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's retained earnings has grown at a 13.1% compound annual growth rate (CAGR), from -$223.14M to -$412.29M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.